GW Pharmaceuticals plc is a United Kingdom-based company. The Company is engaged in the research, development and commercialization of a range of cannabinoid prescription medicines to meet patient needs in a range of medical conditions. The Company is developing a portfolio of cannabinoid medicines, of which the main product is Sativex, an oromucosal spray for the treatment of Multiple Sclerosis (MS) symptoms, cancer pain and neuropathic pain.
MMJ PhytoTech Limited (ASX:MMJ) is pleased to advise that results from the Phase 1 Clinical Trial undertaken by MMJ's wholly-owned, Israeli-based subsidiary PhytoTech Therapeutics Ltd have been published.
MMJ PhytoTech Limited (ASX:MMJ) is pleased to advise that its wholly-owned, Israeli-based subsidiary PhytoTech Therapeutics Limited ("PTL"), will commence a Phase 2 clinical study into the efficacy of the its PTL101 capsules in treating intractable epilepsy in children.
MMJ PhytoTech Limited (ASX:MMJ) is pleased to provide its shareholders with the below Company update, in the form of a Q&A session with Managing Director Andreas Gedeon.
PhytoTech Medical Limited (ASX:PYL), the Australian owned Medical Grade Cannabis (MGC) company and the first MGC company to list on the Australian Stock Exchange, today announces that the research and development into its delivery systems for administering Medical Grade Cannabis (MGC) based therapeutic products has now commenced.
